Literature DB >> 11912545

Treatment with atorvastatin ameliorates hepatic very-low-density lipoprotein overproduction in an animal model of insulin resistance, the fructose-fed Syrian golden hamster: evidence that reduced hypertriglyceridemia is accompanied by improved hepatic insulin sensitivity.

Leyla Mangaloglu1, Raphael C Cheung, Stephen C Van Iderstine, Changiz Taghibiglou, Louisa Pontrelli, Khosrow Adeli.   

Abstract

A novel animal model of insulin resistance, the fructose-fed Syrian golden hamster has been previously documented to exhibit considerable hepatic very-low-density lipoprotein (VLDL) overproduction concomitant with the development of whole body insulin resistance. Here, we investigated whether hepatic lipoprotein overproduction can be ameliorated by treatment with a hydroxymethyl glutaryl conenzyme A (HMG-CoA) reductase inhibitor, atorvastatin, using a series of ex vivo experiments. Hamsters were fed a fructose-enriched diet for 14 days to induce a state of insulin resistance, and then continued on a fructose-enriched diet supplemented with or without 40 mg/kg atorvastatin per day for 14 days. Fructose feeding in the first 2 weeks caused a significant increase in plasma total cholesterol and triglyceride levels. There was a significant decline in plasma triglyceride levels following supplementation with the inhibitor (50% to 59%; P <.05). Experiments with primary hepatocytes revealed a decreased VLDL-apolipoprotein B (apoB) production (37.4% +/- 10.4%; P <.05) in hamsters treated with atorvastatin. Interestingly, atorvastatin treatment partially attenuated (by 23%) the elevated hepatic level of microsomal triglyceride transfer protein (MTP) induced by fructose feeding. There was molecular evidence of improved hepatic insulin sensitivity with atorvastatin treatment based on assessment of the phosphorylation status of the insulin receptor and the expression of protein tyrosine phosphatase-1B. The improvement in insulin signaling was not mediated by a change in hepatic triglyceride accumulation as no significant difference was observed in liver triglyceride levels. Taken together, these data suggest that statins can ameliorate the VLDL-apoB overproduction state observed in a fructose-fed, insulin-resistant hamster model, and may potentially contribute to an enhanced hepatic insulin sensitivity. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11912545     DOI: 10.1053/meta.2002.30954

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  6 in total

1.  Development of Wistar rat model of insulin resistance.

Authors:  Jing Ai; Ning Wang; Mei Yang; Zhi-Min Du; Yong-Chun Zhang; Bao-Feng Yang
Journal:  World J Gastroenterol       Date:  2005-06-28       Impact factor: 5.742

2.  PPARδ activation induces hepatic long-chain acyl-CoA synthetase 4 expression in vivo and in vitro.

Authors:  Chin Fung Kelvin Kan; Amar Bahadur Singh; Bin Dong; Vikram Ravindra Shende; Jingwen Liu
Journal:  Biochim Biophys Acta       Date:  2015-01-31

3.  Genetically Engineered Hamster Models of Dyslipidemia and Atherosclerosis.

Authors:  Xunde Xian; Yuhui Wang; George Liu
Journal:  Methods Mol Biol       Date:  2022

4.  Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study.

Authors:  Vassilios G Athyros; Olga Giouleme; Emmanouel S Ganotakis; Moses Elisaf; Konstantinos Tziomalos; Themistoklis Vassiliadis; Evangelos N Liberopoulos; Eleni Theocharidou; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  Arch Med Sci       Date:  2011-11-08       Impact factor: 3.318

5.  Pharmacological management of metabolic syndrome and its lipid complications.

Authors:  T Binesh Marvasti; Kh Adeli
Journal:  Daru       Date:  2010       Impact factor: 3.117

6.  The role of atorvastatin on the restenosis process post-PTA in a diabetic rabbit model.

Authors:  Xiaojun Zhou; Yaru Mou; Xue Shen; Tianshu Yang; Ju Liu; Fupeng Liu; Jianjun Dong; Lin Liao
Journal:  BMC Cardiovasc Disord       Date:  2016-07-16       Impact factor: 2.298

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.